|
FDA approves first angiogenesis inhibitor to treat colorectal cancer.
Publication: M2 Presswire Publication Date: 27-FEB-04 |
|
|
|
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
|
|
|
COPYRIGHT 2004 Ingram Investment Ltd.
M2 PRESSWIRE-27 February 2004-US FDA: FDA approves first angiogenesis inhibitor to treat colorectal cancer(C)1994-2004 M2 COMMUNICATIONS LTD
RDATE:02262004
FDA today approved Avastin (bevacizumab) as a first-line treatment for patients with metastatic colorectal cancer -- cancer that has spread to other parts of the body. Avastin, a monoclonal antibody, is the first product to be approved that works by preventing the formation of new blood vessels, a process known as angiogenesis. Avastin was shown to extend patients' lives by about five months when given intravenously as a combination treatment along with standard chemotherapy drugs for colon cancer (the "Saltz...
Read the full article for free courtesy of your local library.
|
|
|
|
 |
| More Articles from M2 Presswire |
Call centers to lavish over $1bn on improving customer service, agent ...
February 27, 2004
|
New funding to boost radiography workforce.
February 27, 2004
|
Oswestry driving test centre to relocate.
February 27, 2004
|
FSA issues Freedom of Information publication scheme.
February 27, 2004
|
Shop watch launched at New Scotland Yard.
February 27, 2004
|
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
